US-based device company Nevro has secured market authorisation from the European Union (EU) for its HFX iQ spinal cord ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

Nevro Corp. NVRO reported a loss per share of 41 cents in the third quarter of 2024, narrower than the year-ago quarter’s ...

The company announced receiving CE Mark Certification in Europe for its HFX iQ spinal cord stimulation system. Nevro raised ...

Nevro (NYSE:NVRO) announced today that it received CE mark in Europe for its HFX iQ spinal cord stimulation (SCS) system.

Nevro shares surged 21% after better-than-expected revenue in its latest quarter. Shares were trading around $6.44. The stock is down 75% on the year.

Nevro Corp (NVRO) has disclosed a new risk, in the Accounting & Financial Operations category. Nevro Corp faces a significant financial risk due to potential declines in its market capitalization, ...

Baird raised the firm’s price target on Nevro (NVRO) to $6 from $5 and keeps a Neutral rating on the shares. The firm said it remains a show-me story as the business transformation remains underway.

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

Nevro (NYSE:NVRO – Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, ...

Nevro's HFX iQ spinal cord stimulator earned the European Union's CE mark, the company said Nov. 12.

The Redwood City, California-based company said it had a loss of 41 cents per share. Losses, adjusted for non-recurring gains, came to 51 cents per share. The results exceeded Wall Street expectations ...